Collplant Biotechnologies Ltd Total Liabilities
Collplant Biotechnologies Ltd total liabilities. Based on the latest financial reports, Collplant Biotechnologies Ltd (CLGN) has total liabilities worth $4.78 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check CLGN financial resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Collplant Biotechnologies Ltd (2012–2024)
Total liabilities of Collplant Biotechnologies Ltd from 2012 to 2024. This chart illustrates how Collplant Biotechnologies Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore long-term investment intensity of Collplant Biotechnologies Ltd to see how much of total assets are deployed in long-term investments.
Collplant Biotechnologies Ltd Competitors by Total Liabilities
The table below lists competitors of Collplant Biotechnologies Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Radiant Utama Interinsco Tbk
JK:RUIS
|
Indonesia | Rp711.69 Billion |
|
Lite Access Technologies Inc
V:LTE
|
Canada | CA$27.15 Million |
|
Quoin Pharmaceuticals Ltd DRC
NASDAQ:QNRX
|
USA | $8.04 Million |
|
Dovre Group Plc
HE:DOV1V
|
Finland | €71.17 Million |
|
Coloured Ties Capital Inc
V:TIE
|
Canada | CA$2.24 Million |
|
SG COMPANY S.P.A.
F:7KZ
|
Germany | €28.49 Million |
|
Nexted Group Ltd
AU:NXD
|
Australia | AU$97.66 Million |
|
Emerson Radio Corporation
NYSE MKT:MSN
|
USA | $1.41 Million |
Liability Composition Analysis (2012–2024)
This chart breaks down Collplant Biotechnologies Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Collplant Biotechnologies Ltd balance sheet assets.
Liquidity & Leverage Metrics
Collplant Biotechnologies Ltd Total Liabilities Ratios Explained
Collplant Biotechnologies Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.66 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.51 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.34 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Collplant Biotechnologies Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Collplant Biotechnologies Ltd (2012–2024)
The table below shows the annual total liabilities of Collplant Biotechnologies Ltd from 2012 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $5.25 Million | -9.35% |
| 2023-12-31 | $5.79 Million | +5.45% |
| 2022-12-31 | $5.49 Million | -10.09% |
| 2021-12-31 | $6.10 Million | -4.10% |
| 2020-12-31 | $6.36 Million | -4.50% |
| 2019-12-31 | $6.66 Million | +55.35% |
| 2018-12-31 | $4.29 Million | -21.37% |
| 2017-12-31 | $5.46 Million | +126.31% |
| 2016-12-31 | $2.41 Million | +150.95% |
| 2015-12-31 | $960.64K | +41.32% |
| 2014-12-31 | $679.77K | -25.77% |
| 2013-12-31 | $915.72K | +14.77% |
| 2012-12-31 | $797.87K | -- |
About Collplant Biotechnologies Ltd
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. The company's products are based on its recombinant human collagen (rhCollagen) that is produced using its proprietary technology. It offers regenerative dermal … Read more